Physician profile
Cindy Alvarez
NPI 1053176628
$8,603.26
in general payments reported to CMS, 2019-2025
21 companies · $6,999 in 2025
The $6,999 reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,604 · 2025: $6,999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,637 · Consulting Fee: $2,720 · Travel and Lodging: $1,152 · Education: $95.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,636.51 |
| Consulting Fee | $2,720.00 |
| Travel and Lodging | $1,151.71 |
| Education | $95.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $4,730.33 | 2024-2025 | |
| Glaxosmithkline, LLC. | $660.17 | 2024-2025 | Nucala, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $567.99 | 2024-2025 | Winrevair, Zerbaxa, Recarbrio |
| Astrazeneca Pharmaceuticals Lp | $463.40 | 2024-2025 | Breztri, Tezspire, Fasenra |
| Actelion Pharmaceuticals US, INC. | $359.14 | 2024-2025 | Uptravi, Opsumit, Opsynvi |
| Regeneron Healthcare Solutions, INC. | $317.25 | 2024-2025 | Dupixent |
| Bayer Healthcare Pharmaceuticals INC. | $300.23 | 2024-2025 | |
| Verona Pharma, INC. | $228.80 | 2025 | Ohtuvayre |
| United Therapeutics Corporation | $219.82 | 2024-2025 | Tyvaso, Tyvaso |
| Insmed, INC. | $200.34 | 2024-2025 | Arikayce, Brinsupri |
| Philips North America LLC | $145.14 | 2025 | Respiratory, Encore, Vest Therapy Und |
| Revance Therapeutics, INC. | $116.29 | 2024 | Daxxify |
| Grifols USA, LLC | $63.08 | 2024-2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.18 | 2024-2025 | Ofev |
| Inspire Medical Systems, INC. | $38.78 | 2025 | Inspire |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $31.30 | 2025 | Smartvest |
| Vifor Pharma, INC. | $27.81 | 2025 | Zemaira |
| Baxter Healthcare | $22.60 | 2025 | Hillrom - Volara System |
| Avadel Cns Pharmaceuticals, LLC | $21.21 | 2025 | Lumryz |
| Janssen Biotech, INC. | $17.87 | 2024 | Imbruvica, Darzalex |
| Lilly USA, LLC | $14.53 | 2024 | Jaypirca, Verzenio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.